You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
诺辉健康-B(06606.HK):与阿斯利康合作冀助「常卫清」渗透市场 短期无降价计划
阿思达克 03-16 11:22
诺辉健康-B(06606.HK)公布与阿斯利康(AZN.US)签订合作推广协议,双方将共同在中国大陆地区公立医院及药店和互联网医院,推广结直肠癌筛查测试产品「常卫清」。公司首席执行官朱叶青在全年业绩网上会议表示,阿斯利康为最国际化的药企,且於中国的销售人员达4,000人,相信是次合作有助公司将产品进一步渗透市场,公司亦会扩大有关销售团队的规模,期望由今年首季的约100人,增至年底的约500人。

他指,希望公司的产品尽快进入更多医院及体检中心销售,相信透过加深与保险及互联网医疗商等的合作,可令产品的认知度及渗透度提高。公司目标为於2025年的医院渗透率升至5%,体检中心销售扩至1,000间,及三至五年的市场渗透增至20%。

首席财务官高煜则称,「常卫清」是中国目前唯一获国家药监局批准的结直肠癌筛查能够测试癌前病变,由於临床时间长,相信该产品未来五年内并无竞争对手,因此公司短期没有降价计划。而公司对成本非常重视,会藉第三方检测的规模效应,及推进全自动化生产等降低成本及提升毛利率。

另外,主席兼首席科学官陈一友提到,公司与阿斯利康亦有合作发展海外市场的潜力,目前较关注的市场包括距离较近、相对容易接受中国标准及基因构成较为相似的市场,例如东南亚、日韩及印度等地,不过目前未有具体目标发展市场。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account